<DOC>
	<DOCNO>NCT01071642</DOCNO>
	<brief_summary>The aim current study evaluate prospectively whether concomitant administration RAAS blocker ( namely ACE-I ARBs ' ) influence change estimate GFR ( eGFR ) administration contrast medium patient undergo non-emergent coronary angiography .</brief_summary>
	<brief_title>The Influence Angiotensin Converting Enzyme Inhibitors Angiotensin Receptor Blockers Renal Function Patients Undergoing Non-emergent Coronary Angiography</brief_title>
	<detailed_description />
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Subjects chronic therapy ACEI and/or ARBs ' ( confirm electronic record medical file ) 3 . Subjects plan undergo nonemergent coronary angiography . 4 . Signed informed consent 1. eGFR &lt; 30 ml/min baseline 2 . Chronic utilization NSAIDS Cox2 selective inhibitor 3 . Chronic treatment mineralocorticosteroid receptor blocker 4 . Systolic blood pressure &lt; 90 mmHg 5 . Planned stag ( repeat ) procedure within 48 hour 6 . Administration contrast within 14 day prior enrollment 7. contraindication stop ACEI ARB 'S</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Change eGFR baseline 72 hour follow exposure contrast .</keyword>
	<keyword>Rate eGFR decrease &gt; 25 % baseline</keyword>
	<keyword>Length hospitalization .</keyword>
	<keyword>Requirement unplanned therapy elevate blood pressure</keyword>
</DOC>